Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanoma - agenti antineoplastici - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 e 5. il trattamento adiuvante di melanomadabrafenib in combinazione con trametinib è indicato per il trattamento adiuvante di pazienti adulti con melanoma in stadio iii con un braf v600 mutazione, a seguito di una completa resezione. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - dabrafenibum - capsule rigide - dabrafenibum 50 mg ut dabrafenibi mesilas, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - dabrafenibum - capsule rigide - dabrafenibum 75.0 mg ut dabrafenibi mesilas, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - dabrafenibum - tablette zur herstellung einer suspension zum einnehmen - dabrafenibum 10 mg ut dabrafenibi mesilas, mannitolum, cellulosum microcristallinum, crospovidonum, hypromellosum, acesulfamum kalicum magnesii stearas, silica colloidalis anhydrica, aromatica beerengeschmack alcohol benzylicus 0.00078 mg cum propylenglycolum 0.036 mg cum pro compresso. - onkologikum - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - trametinib - melanoma - agenti antineoplastici - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 e 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non a piccole cellule del polmone (nsclc)trametinib in combinazione con dabrafenib è indicato per il trattamento di pazienti adulti con avanzato non a piccole cellule cancro ai polmoni con una braf v600 mutazione.

Unione Europea - italiano - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine, lamivudina, tenofovir disoproxil fumarato - infezioni da hiv - antivirali per il trattamento delle infezioni da hiv, combinazioni - delstrigo è indicato per il trattamento di adulti infettati con hiv 1 senza passato o presente, la prova di resistenza agli nnrti classe, lamivudina, o tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Unione Europea - italiano - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine - infezioni da hiv - antivirali per uso sistemico - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Unione Europea - italiano - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - tumori stromali gastrointestinali - altri agenti antineoplastici, inibitori della proteina chinasi - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Unione Europea - italiano - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplasie al seno - terapia endocrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

pfizer italia s.r.l. - gemfibrozil - gemfibrozil